The abstract submission is now closed
Abstract submission deadlines
Deadline |
Date and time |
|---|---|
|
Abstracts Trial in Progress Intent to submit LBA |
1 October 2024, 21:00hrs CEST (CEST = Central European Summer Time) |
Late-breaking abstracts (LBA) |
6 November 2024, 21:00hrs CET (CET = Central European Time) A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline 1 October 2024. |
Outcome notifications
Outcome notifications of regular abstracts are expected to be made available to first authors and submitters by end-October 2024.
Outcome notifications of accepted full LBAs are expected to be made available to first authors and submitters by mid-Nov 2024.
Information for presenters
Detailed instructions for the preparation of slide presentations and/or posters will be made available by end-October in the section “Information for Presenters”.
Abstract submission categories
- Biomarker development
- Cell therapy/Immune engineering
- Clinical practice
- Therapeutic development
- Tumour biology and tumour microenvironment
- Miscellaneous
Late-breaking abstracts
Late-breaking abstracts may be submitted for high quality, new research findings with implications for clinical practice or understanding of disease processes.
The final late-breaking abstract deadline of 6 November 2024 is under no circumstances to be considered as an extension of the general submission deadline (1 October 2024).
Trial in Progress abstracts
Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ESMO Immuno-Oncology Congress 2024.
It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.
Presentation and publication of accepted abstracts
The ESMO Immuno-Oncology Congress 2024 Scientific Committee will select abstracts for presentation during the Congress and determine the format of the presentations from the following possibilities:
- Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
- Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
- Poster – Display session for review, discussion and questions. The presenting authors must be available onsite for Q&A to represent their work.
Accepted abstracts, including late-breaking abstracts, will be published online only in the ESMO Immuno-Oncology Congress 2024 Abstract Book, a supplement to the official ESMO journal, ESMO IOTECH.
Publication schedule of accepted abstracts
Details regarding the publication of accepted abstracts are available here.
ESMO Merit Travel Grant
A restricted number of ESMO Merit Travel Grants to the the ESMO Immuno-Oncology Congress 2024 are available, upon application, to first author (= presenter) who submit abstracts considered to be deserving of recognition. Candidates must be ESMO Members under the age of 40. Selection will be made by the the ESMO Immuno-Oncology Congress 2024 Scientific Committee on a competitive basis from among the accepted abstracts.